Cargando…

The Global Landscape of Manufacturers of Follow-on Biologics: An Overview of Five Major Biosimilar Markets and 15 Countries

BACKGROUND: Current knowledge is limited about which manufacturers are active in the global field of biopharmaceutical product development and how many unique follow-on biologics are approved in global markets. OBJECTIVE: This study aimed to provide a cross-sectional overview of manufacturers of fol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Klein, Kevin, Gencoglu, Mümün, Heisterberg, Jens, Acha, Virginia, Stolk, Pieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971138/ https://www.ncbi.nlm.nih.gov/pubmed/36472773 http://dx.doi.org/10.1007/s40259-022-00568-0

Ejemplares similares

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?
por: Klein, Kevin, et al.
Publicado: (2022)

Policies for biosimilar uptake in Europe: An overview
por: Moorkens, Evelien, et al.
Publicado: (2017)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Biomedical and Market Issues Surrounding the Advent of Biosimilars
por: Cline, Abigail, et al.
Publicado: (2016)

Cell line access to revolutionize the biosimilars market
por: Gotham, Dzintars
Publicado: (2018)

Key drivers for market penetration of biosimilars in Europe
por: Rémuzat, Cécile, et al.
Publicado: (2017)

An Overview of the Policy and Market Landscape of Tobacco Production and Control in Mozambique
por: Nguenha, Nicole, et al.
Publicado: (2021)

Emerging Insights into European Markets of Biologics, Including Biosimilars
por: Simoens, Steven, et al.
Publicado: (2022)

An international comparative analysis and roadmap to sustainable biosimilar markets
por: Alnaqbi, Khalid A., et al.
Publicado: (2023)

Analytical Similarity Assessment of Biosimilars: Global Regulatory Landscape, Recent Studies and Major Advancements in Orthogonal Platforms
por: Nupur, Neh, et al.
Publicado: (2022)

An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins
por: Heinemann, Lutz, et al.
Publicado: (2015)

Biosimilars: Company Strategies to Capture Value from the Biologics Market
por: Calo-Fernández, Bruno, et al.
Publicado: (2012)

The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland
por: Luukkanen, Saana V., et al.
Publicado: (2022)

Biosimilars in inflammatory bowel disease: A review of post-marketing experience
por: Deiana, Simona, et al.
Publicado: (2017)

An Overview of the Additive Manufacturing of Bast Fiber-Reinforced Composites and Envisaging Advancements Using the Patent Landscape
por: Balaji, Devarajan, et al.
Publicado: (2023)

Rituximab in the treatment of follicular lymphoma: the future of biosimilars in the evolving therapeutic landscape
por: Subramanian, Janakiraman, et al.
Publicado: (2017)

Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany
por: Moorkens, Evelien, et al.
Publicado: (2020)

How Similar Are Biosimilars? What Do Clinicians Need to Know About Biosimilar and Follow-On Insulins?
por: Triplitt, Curtis, et al.
Publicado: (2017)

Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends
por: Car, Elif, et al.
Publicado: (2023)

The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019
por: Kang, Hye-Na, et al.
Publicado: (2020)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Contract manufacturing, market competition, and labor productivity in US manufacturing industries
por: Wu, Dazhong, et al.
Publicado: (2022)

The impact of the Covid-19 related media coverage upon the five major developing markets
por: Umar, Zaghum, et al.
Publicado: (2021)

Partnership for productive development of biosimilar products: perspectives of access to biological products in the Brazilian market
por: Scheinberg, Morton Aaron, et al.
Publicado: (2018)

Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market
por: Dean, Emma Boswell, et al.
Publicado: (2021)

Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets
por: Jang, Minyoung, et al.
Publicado: (2020)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Creating business agility: how convergence of cloud, social, mobile, video, and big data enables competitive advantage
por: Heisterberg, Rodney, et al.
Publicado: (2014)

The complexity and cost of vaccine manufacturing – An overview
por: Plotkin, Stanley, et al.
Publicado: (2017)

Fish Innate Immune Response to Viral Infection—An Overview of Five Major Antiviral Genes
por: Ortega-Villaizan, Maria del Mar, et al.
Publicado: (2022)

The Impact of Manufacturer Coupon Use in the Statin Market
por: Daugherty, Jonas B., et al.
Publicado: (2013)

Assessment of the Opportunities for Pharmaceutical Manufacturers in Emerging Markets
por: Anderson, Tim, et al.
Publicado: (2009)

Supply-side and demand-side policies for biosimilars: an overview in 10 European member states
por: Rémuzat, Cécile, et al.
Publicado: (2017)

Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
por: Dutta, Binita, et al.
Publicado: (2019)

The Budget Impact of Biosimilar Infliximab (Remsima(®)) for the Treatment of Autoimmune Diseases in Five European Countries
por: Jha, Ashok, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vatr94712f1lptjdj2qkvls6pc